Impact of aortic valve closure on adverse events and outcomes with the HeartWare ventricular assist device

David Dobarro, Marian Urban, Karen Booth, Neil Wrightson, Javier Castrodeza, Jerome Jungschleger, Nicola Robinson-Smith, Andrew Woods, Gareth Parry, Stephan Schueler, Guy A. MacGowan

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background This study examined whether aortic valve opening (AVO) and other echocardiographic parameters influence outcomes in patients on left ventricular (LV) assist device (LVAD) support. Pump thrombosis (PT) and ischemic stroke (IS) are known complications of LVAD, but mechanisms that could influence them are not completely understood. Methods This was a retrospective analysis of 147 patients who received a HeartWare Ventricular Assist Device ( HeartWare International) as a bridge to transplant or to candidacy between July 2009 and August 2015, of whom 126 had at least 30 days of follow-up before the first event (30-days-out cohort). Outcomes included survival, PT, IS, and PT+IS (combined thrombotic event; CTE). Results Median time on support was 518 days. Of the 30-days-out cohort, 29% had a first PT and 19% a first IS. AVO was associated with longer survival on device (1,081 vs 723 days; p = 0.01) in the entire cohort. In the 30-days-out cohort, the aortic valve was more frequently closed in patients with lower ejection fractions on support (14% ± 6% vs 18% ± 9%; p = 0.009), more dilated pre-event echocardiogram (LV end-diastolic diameter, 66 ± 12 mm vs 62 ± 10 mm; p = 0.04), and pre-implant LV end-diastolic diameter (70 ± 10 mm vs 66 ± 9 mm; p = 0.06). CTE-free survival on the device was lower with a closed aortic valve (897 vs 1,314 days; p = 0.003) as was PT-free survival on the device (1,070 vs 1,457 days; p = 0.02). Cox regression analysis showed that AVO was an independent predictor of CTE (p = 0.03) Conclusions Thrombotic events are relatively frequent in patients on long-term LVAD support. A closed aortic valve was associated with decreased overall survival, thrombosis-free survival, and poorer LV function on support. These are high-risk patients, so whether they require more intense anti-coagulation or prioritizing for transplantation requires further research.

Original languageEnglish (US)
Pages (from-to)42-49
Number of pages8
JournalJournal of Heart and Lung Transplantation
Volume36
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Heart-Assist Devices
Aortic Valve
Thrombosis
Survival
Equipment and Supplies
Stroke
Left Ventricular Function
Transplantation
Regression Analysis
Transplants
Research

Keywords

  • aortic valve opening
  • ischemic stroke
  • left ventricular assist device
  • left ventricular end-diastolic dimension
  • pump thrombosis

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine
  • Transplantation

Cite this

Impact of aortic valve closure on adverse events and outcomes with the HeartWare ventricular assist device. / Dobarro, David; Urban, Marian; Booth, Karen; Wrightson, Neil; Castrodeza, Javier; Jungschleger, Jerome; Robinson-Smith, Nicola; Woods, Andrew; Parry, Gareth; Schueler, Stephan; MacGowan, Guy A.

In: Journal of Heart and Lung Transplantation, Vol. 36, No. 1, 01.01.2017, p. 42-49.

Research output: Contribution to journalArticle

Dobarro, D, Urban, M, Booth, K, Wrightson, N, Castrodeza, J, Jungschleger, J, Robinson-Smith, N, Woods, A, Parry, G, Schueler, S & MacGowan, GA 2017, 'Impact of aortic valve closure on adverse events and outcomes with the HeartWare ventricular assist device', Journal of Heart and Lung Transplantation, vol. 36, no. 1, pp. 42-49. https://doi.org/10.1016/j.healun.2016.08.006
Dobarro, David ; Urban, Marian ; Booth, Karen ; Wrightson, Neil ; Castrodeza, Javier ; Jungschleger, Jerome ; Robinson-Smith, Nicola ; Woods, Andrew ; Parry, Gareth ; Schueler, Stephan ; MacGowan, Guy A. / Impact of aortic valve closure on adverse events and outcomes with the HeartWare ventricular assist device. In: Journal of Heart and Lung Transplantation. 2017 ; Vol. 36, No. 1. pp. 42-49.
@article{018da2a5aca0435eb8f653cbc443c60f,
title = "Impact of aortic valve closure on adverse events and outcomes with the HeartWare ventricular assist device",
abstract = "Background This study examined whether aortic valve opening (AVO) and other echocardiographic parameters influence outcomes in patients on left ventricular (LV) assist device (LVAD) support. Pump thrombosis (PT) and ischemic stroke (IS) are known complications of LVAD, but mechanisms that could influence them are not completely understood. Methods This was a retrospective analysis of 147 patients who received a HeartWare Ventricular Assist Device ( HeartWare International) as a bridge to transplant or to candidacy between July 2009 and August 2015, of whom 126 had at least 30 days of follow-up before the first event (30-days-out cohort). Outcomes included survival, PT, IS, and PT+IS (combined thrombotic event; CTE). Results Median time on support was 518 days. Of the 30-days-out cohort, 29{\%} had a first PT and 19{\%} a first IS. AVO was associated with longer survival on device (1,081 vs 723 days; p = 0.01) in the entire cohort. In the 30-days-out cohort, the aortic valve was more frequently closed in patients with lower ejection fractions on support (14{\%} ± 6{\%} vs 18{\%} ± 9{\%}; p = 0.009), more dilated pre-event echocardiogram (LV end-diastolic diameter, 66 ± 12 mm vs 62 ± 10 mm; p = 0.04), and pre-implant LV end-diastolic diameter (70 ± 10 mm vs 66 ± 9 mm; p = 0.06). CTE-free survival on the device was lower with a closed aortic valve (897 vs 1,314 days; p = 0.003) as was PT-free survival on the device (1,070 vs 1,457 days; p = 0.02). Cox regression analysis showed that AVO was an independent predictor of CTE (p = 0.03) Conclusions Thrombotic events are relatively frequent in patients on long-term LVAD support. A closed aortic valve was associated with decreased overall survival, thrombosis-free survival, and poorer LV function on support. These are high-risk patients, so whether they require more intense anti-coagulation or prioritizing for transplantation requires further research.",
keywords = "aortic valve opening, ischemic stroke, left ventricular assist device, left ventricular end-diastolic dimension, pump thrombosis",
author = "David Dobarro and Marian Urban and Karen Booth and Neil Wrightson and Javier Castrodeza and Jerome Jungschleger and Nicola Robinson-Smith and Andrew Woods and Gareth Parry and Stephan Schueler and MacGowan, {Guy A.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/j.healun.2016.08.006",
language = "English (US)",
volume = "36",
pages = "42--49",
journal = "Journal of Heart and Lung Transplantation",
issn = "1053-2498",
publisher = "Elsevier USA",
number = "1",

}

TY - JOUR

T1 - Impact of aortic valve closure on adverse events and outcomes with the HeartWare ventricular assist device

AU - Dobarro, David

AU - Urban, Marian

AU - Booth, Karen

AU - Wrightson, Neil

AU - Castrodeza, Javier

AU - Jungschleger, Jerome

AU - Robinson-Smith, Nicola

AU - Woods, Andrew

AU - Parry, Gareth

AU - Schueler, Stephan

AU - MacGowan, Guy A.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background This study examined whether aortic valve opening (AVO) and other echocardiographic parameters influence outcomes in patients on left ventricular (LV) assist device (LVAD) support. Pump thrombosis (PT) and ischemic stroke (IS) are known complications of LVAD, but mechanisms that could influence them are not completely understood. Methods This was a retrospective analysis of 147 patients who received a HeartWare Ventricular Assist Device ( HeartWare International) as a bridge to transplant or to candidacy between July 2009 and August 2015, of whom 126 had at least 30 days of follow-up before the first event (30-days-out cohort). Outcomes included survival, PT, IS, and PT+IS (combined thrombotic event; CTE). Results Median time on support was 518 days. Of the 30-days-out cohort, 29% had a first PT and 19% a first IS. AVO was associated with longer survival on device (1,081 vs 723 days; p = 0.01) in the entire cohort. In the 30-days-out cohort, the aortic valve was more frequently closed in patients with lower ejection fractions on support (14% ± 6% vs 18% ± 9%; p = 0.009), more dilated pre-event echocardiogram (LV end-diastolic diameter, 66 ± 12 mm vs 62 ± 10 mm; p = 0.04), and pre-implant LV end-diastolic diameter (70 ± 10 mm vs 66 ± 9 mm; p = 0.06). CTE-free survival on the device was lower with a closed aortic valve (897 vs 1,314 days; p = 0.003) as was PT-free survival on the device (1,070 vs 1,457 days; p = 0.02). Cox regression analysis showed that AVO was an independent predictor of CTE (p = 0.03) Conclusions Thrombotic events are relatively frequent in patients on long-term LVAD support. A closed aortic valve was associated with decreased overall survival, thrombosis-free survival, and poorer LV function on support. These are high-risk patients, so whether they require more intense anti-coagulation or prioritizing for transplantation requires further research.

AB - Background This study examined whether aortic valve opening (AVO) and other echocardiographic parameters influence outcomes in patients on left ventricular (LV) assist device (LVAD) support. Pump thrombosis (PT) and ischemic stroke (IS) are known complications of LVAD, but mechanisms that could influence them are not completely understood. Methods This was a retrospective analysis of 147 patients who received a HeartWare Ventricular Assist Device ( HeartWare International) as a bridge to transplant or to candidacy between July 2009 and August 2015, of whom 126 had at least 30 days of follow-up before the first event (30-days-out cohort). Outcomes included survival, PT, IS, and PT+IS (combined thrombotic event; CTE). Results Median time on support was 518 days. Of the 30-days-out cohort, 29% had a first PT and 19% a first IS. AVO was associated with longer survival on device (1,081 vs 723 days; p = 0.01) in the entire cohort. In the 30-days-out cohort, the aortic valve was more frequently closed in patients with lower ejection fractions on support (14% ± 6% vs 18% ± 9%; p = 0.009), more dilated pre-event echocardiogram (LV end-diastolic diameter, 66 ± 12 mm vs 62 ± 10 mm; p = 0.04), and pre-implant LV end-diastolic diameter (70 ± 10 mm vs 66 ± 9 mm; p = 0.06). CTE-free survival on the device was lower with a closed aortic valve (897 vs 1,314 days; p = 0.003) as was PT-free survival on the device (1,070 vs 1,457 days; p = 0.02). Cox regression analysis showed that AVO was an independent predictor of CTE (p = 0.03) Conclusions Thrombotic events are relatively frequent in patients on long-term LVAD support. A closed aortic valve was associated with decreased overall survival, thrombosis-free survival, and poorer LV function on support. These are high-risk patients, so whether they require more intense anti-coagulation or prioritizing for transplantation requires further research.

KW - aortic valve opening

KW - ischemic stroke

KW - left ventricular assist device

KW - left ventricular end-diastolic dimension

KW - pump thrombosis

UR - http://www.scopus.com/inward/record.url?scp=85006094621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006094621&partnerID=8YFLogxK

U2 - 10.1016/j.healun.2016.08.006

DO - 10.1016/j.healun.2016.08.006

M3 - Article

C2 - 27776988

AN - SCOPUS:85006094621

VL - 36

SP - 42

EP - 49

JO - Journal of Heart and Lung Transplantation

JF - Journal of Heart and Lung Transplantation

SN - 1053-2498

IS - 1

ER -